Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma

MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis

“…While the predictive value of cytogenetical abnormalities, immunoglobulin heavy chain gene mutation status, CD38 and ZAP70 expression is already well known, the significance of multidrug resistance in CLL is not well characterized, and an evaluation of MDR1 polymorphisms is of uncertain prognostic value. In fact, although previous studies of polymorphism in MDR1 gene exons 21 and 26 revealed that T2677T and T3435T alleles are not a factor predisposing to lymphoproliferative diseases or multiple myeloma [24,25], nevertheless in CLL conflicting results have been published, and MDR1 expression was detected in 0-100% of the patients analyzed in different studies [26].…”

The importance of C1236T polymorphism in the ABCB1/MDR1 gene in assessment of susceptibility to inflammatory bowel diseases in the Polish population

“…Among healthy volunteers from the Lodz region in central Poland, who constituted the control group, the frequency of 1236CC, 1236CT, 1236TT genotypes was 45.7%, 35.7%, 18.6%, respectively (Table II) [13,16,[21][22][23]. It has been observed that in our group of healthy volunteers from the Lodz region the 1236CC genotype occurred more frequently as compared to other populations, which may result from the different number of studied individuals.…”

“…The obtained values are higher but comparable to published data concerning German and French populations (59.0% for the 1236C allele, 41.0% for the 1236T allele [16,22]), and a Czech population (55.5% for the 1236C allele, 44.5% for the 1236T allele [21]). Jamroziak et al observed that 1236C allele carriers accounted for 57.3%, and 1236T allele carriers for 42.7% in the Polish population [23]. Results of a study conducted in a Turkish population indicated more frequent occurrence of the 1236T allele (54.5%) than the 1236C allele (45.5%) [13].…”

Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case–control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium

“…11 Therefore, we performed a two-phase candidate gene association study to comprehensively evaluate the role of genetic variants of ABCs transporter genes in relation to MM risk. We selected 54 SNPs in ABCB1, ABCG2 and ABCC2 genes using a tagging approach to take into account for all the common genetic variability within these genes and four additional functional polymorphisms in ABCC1 and ABCC3 to test their impact on MM susceptibility (a complete list of the selected SNPs is available in Supplementary Table I).…”